Loading...
Header Logo
Keywords
Last Name
Institution

JOHN MENDELSOHN

TitleProfessor
InstitutionMD Anderson
DepartmentGenomic Medicine
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Rodon J, Soria JC, Berger R, Miller WH, Rubin E, Kugel A, Tsimberidou A, Saintigny P, Ackerstein A, Braña I, Loriot Y, Afshar M, Miller V, Wunder F, Bresson C, Martini JF, Raynaud J, Mendelsohn J, Batist G, Onn A, Tabernero J, Schilsky RL, Lazar V, Lee JJ, Kurzrock R. Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial. Nat Med. 2019 05; 25(5):751-758. PMID: 31011205.
      View in: PubMed
    2. Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM. Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Mol Cancer Ther. 2019 02; 18(2):399-412. PMID: 30518672.
      View in: PubMed
    3. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018. PMID: 30035249.
      View in: PubMed
    4. Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res. 2018 Jun 15; 24(12):2719-2731. PMID: 29420224.
      View in: PubMed
    5. Brusco LL, Wathoo C, Mills Shaw KR, Holla VR, Bailey AM, Johnson AM, Khotskaya YB, Litzenburger BC, Sanchez NS, Zeng J, Bernstam EV, Eng C, Kee BK, Amaria RN, Routbort MJ, Mills GB, Mendelsohn J, Meric-Bernstam F. Physician interpretation of genomic test results and treatment selection. Cancer. 2018 03 01; 124(5):966-972. PMID: 29165790.
      View in: PubMed
    6. Kurnit KC, Bailey AM, Zeng J, Johnson AM, Shufean MA, Brusco L, Litzenburger BC, Sánchez NS, Khotskaya YB, Holla V, Simpson A, Mills GB, Mendelsohn J, Bernstam E, Shaw K, Meric-Bernstam F. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource. Cancer Res. 2017 11 01; 77(21):e123-e126. PMID: 29092956.
      View in: PubMed
    7. Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA, Piha-Paul S, Subbiah V, Hong D, Routbort M, Broaddus R, Mills Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F. Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017. PMID: 30320296.
      View in: PubMed
    8. Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, Mendelsohn J, Hess KR, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017. PMID: 29082359.
      View in: PubMed
    9. Arango NP, Brusco L, Mills Shaw KR, Chen K, Eterovic AK, Holla V, Johnson A, Litzenburger B, Khotskaya YB, Sanchez N, Bailey A, Zheng X, Horombe C, Kopetz S, Farhangfar CJ, Routbort M, Broaddus R, Bernstam EV, Mendelsohn J, Mills GB, Meric-Bernstam F. A feasibility study of returning clinically actionable somatic genomic alterations identified in a research laboratory. Oncotarget. 2017 Jun 27; 8(26):41806-41814. PMID: 28415679.
      View in: PubMed
    10. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, Khotskaya YB, Sanchez NS, Zeng J, Shufean MA, Shaw KR, Mendelsohn J, Mills GB, Meric-Bernstam F, Simon GR. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud. 2017 Jan; 3(1):a001115. PMID: 28050598.
      View in: PubMed
    11. Basho RK, de Melo Gagliato D, Ueno NT, Wathoo C, Chen H, Shariati M, Wei C, Alvarez RH, Moulder SL, Sahin AA, Roy-Chowdhuri S, Chavez-MacGregor M, Litton JK, Valero V, Luthra R, Zeng J, Shaw KR, Mendelsohn J, Mills GB, Tripathy D, Meric-Bernstam F. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373. PMID: 27806348.
      View in: PubMed
    12. Shen C, Meric-Bernstam F, Su X, Mendelsohn J, Giordano S. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget. 2016 Nov 01; 7(44):71686-71695. PMID: 27634896.
      View in: PubMed
    13. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, Mendelsohn J, Kurzrock R. Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. JAMA Oncol. 2016 Nov 01; 2(11):1452-1459. PMID: 27273579.
      View in: PubMed
    14. Mendelsohn J. Commentary on "Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts" (A Follow Up). Cancer Res. 2016 09 15; 76(18):5192-4. PMID: 27635041.
      View in: PubMed
    15. Jardim DL, Schwaederle M, Lee JJ, Wei C, Mendelsohn J, Schilsky RL, Kurzrock R. Response. J Natl Cancer Inst. 2016 Mar; 108(3):djw001. PMID: 26912651.
      View in: PubMed
    16. Meric-Bernstam F, Shaw K, Mendelsohn J, Mills GB. Reply to M.P. Decatris et al. J Clin Oncol. 2016 Mar 10; 34(8):886. PMID: 26755522.
      View in: PubMed
    17. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam F. Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21. PMID: 26486734.
      View in: PubMed
    18. Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11). PMID: 26378224.
      View in: PubMed
    19. Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. J Clin Oncol. 2015 Nov 10; 33(32):3817-25. PMID: 26304871.
      View in: PubMed
    20. Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam F. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110. PMID: 26015395.
      View in: PubMed
    21. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    22. Johnson A, Zeng J, Bailey AM, Holla V, Litzenburger B, Lara-Guerra H, Mills GB, Mendelsohn J, Shaw KR, Meric-Bernstam F. The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform. Drug Discov Today. 2015 Dec; 20(12):1433-8. PMID: 26148707.
      View in: PubMed
    23. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le Chevalier T, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 2015 Jun 10; 6(16):14139-52. PMID: 25944621.
      View in: PubMed
    24. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, Routbort M, Piha-Paul SA, Janku F, Ueno N, Hong D, De Groot J, Ravi V, Li Y, Luthra R, Patel K, Broaddus R, Mendelsohn J, Mills GB. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62. PMID: 26014291.
      View in: PubMed
    25. Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GB. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25863335.
      View in: PubMed
    26. Mendelsohn J, Ringborg U, Schilsky R. Innovative clinical trials for development of personalized cancer medicine. Mol Oncol. 2015 May; 9(5):933-4. PMID: 25772590.
      View in: PubMed
    27. Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, Zheng X, Gagea M, Chavez-MacGregor M, Ueno NT, Lei X, Zhou W, Nair L, Tripathy D, Brown PH, Hortobagyi GN, Chen K, Mendelsohn J, Mills GB, Gonzalez-Angulo AM. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14. PMID: 25605252.
      View in: PubMed
    28. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, Aldape KD, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Shaw KM, Mendelsohn J, Mills GB, Eterovic AK. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53. PMID: 25626406.
      View in: PubMed
    29. Mendelsohn J, Prewett M, Rockwell P, Goldstein NI. CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clin Cancer Res. 2015 Jan 15; 21(2):227-9. PMID: 25593342.
      View in: PubMed
    30. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515. PMID: 25148578.
      View in: PubMed
    31. Mendelsohn J, Bertagnolli MM. The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges. Semin Oncol. 2014 Aug; 41(4):435-436. PMID: 25173135.
      View in: PubMed
    32. Abernethy A, Abrahams E, Barker A, Buetow K, Burkholder R, Dalton WS, Foti M, Frueh F, Gaynor RB, Kean M, Khan Z, Lessor T, Lichtenfeld JL, Mendelsohn J, van't Veer L. Turning the tide against cancer through sustained medical innovation: the pathway to progress. Clin Cancer Res. 2014 Mar 01; 20(5):1081-6. PMID: 24523437.
      View in: PubMed
    33. Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med. 2014 Feb; 17(92):101-14. PMID: 24534473.
      View in: PubMed
    34. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013 May 20; 31(15):1904-11. PMID: 23589547.
      View in: PubMed
    35. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol. 2013 May 20; 31(15):1849-57. PMID: 23589548.
      View in: PubMed
    36. Farhangfar CJ, Meric-Bernstam F, Mendelsohn J, Mills GB, Lucio-Eterovic AK. The impact of tumor heterogeneity on patient treatment decisions. Clin Chem. 2013 Jan; 59(1):38-40. PMID: 23143327.
      View in: PubMed
    37. Mendelsohn J, Ringborg U, Schilsky RL. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Mol Oncol. 2012 Apr; 6(2):109-10. PMID: 22507633.
      View in: PubMed
    38. Ram PT, Mendelsohn J, Mills GB. Bioinformatics and systems biology. Mol Oncol. 2012 Apr; 6(2):147-54. PMID: 22377422.
      View in: PubMed
    39. Nass SJ, Balogh E, Mendelsohn J. A National Cancer Clinical Trials Network: recommendations from the Institute of Medicine. Am J Ther. 2011 Sep; 18(5):382-91. PMID: 21326081.
      View in: PubMed
    40. Mendelsohn J. A national cancer clinical trials system for targeted therapies. Sci Transl Med. 2011 Mar 23; 3(75):75cm8. PMID: 21430266.
      View in: PubMed
    41. Mendelsohn J, Tursz T, Schilsky RL, Lazar V. WIN Consortium--challenges and advances. Nat Rev Clin Oncol. 2011 Mar; 8(3):133-4. PMID: 21364685.
      View in: PubMed
    42. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell. 2010 Nov 16; 18(5):423-35. PMID: 21075308.
      View in: PubMed
    43. Mendelsohn J. Shaking up cancer clinical trials: an interview with John Mendelsohn, M.D., by Joanne Nicholas. J Natl Cancer Inst. 2010 Aug 18; 102(16):1219-21. PMID: 20693458.
      View in: PubMed
    44. Cardó-Vila M, Giordano RJ, Sidman RL, Bronk LF, Fan Z, Mendelsohn J, Arap W, Pasqualini R. From combinatorial peptide selection to drug prototype (II): targeting the epidermal growth factor receptor pathway. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5118-23. PMID: 20190183.
      View in: PubMed
    45. Slovin SF, Kelly WK, Wilton A, Kattan M, Myskowski P, Mendelsohn J, Scher HI. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus Doxorubicin in the treatment of metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2009 Oct; 7(3):E77-82. PMID: 19815486.
      View in: PubMed
    46. Li X, Lu Y, Liang K, Pan T, Mendelsohn J, Fan Z. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther. 2008 May; 7(5):1207-17. PMID: 18483308.
      View in: PubMed
    47. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res. 2007 Sep 01; 67(17):8240-7. PMID: 17804738.
      View in: PubMed
    48. Cristofanilli M, Mendelsohn J. Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy? Proc Natl Acad Sci U S A. 2006 Nov 14; 103(46):17073-4. PMID: 17090687.
      View in: PubMed
    49. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006 Aug; 33(4):369-85. PMID: 16890793.
      View in: PubMed
    50. Luwor RB, Lu Y, Li X, Mendelsohn J, Fan Z. The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005 Jun 23; 24(27):4433-41. PMID: 15806152.
      View in: PubMed
    51. Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Pötschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. Curbing tobacco's toll starts with the professionals: World No Tobacco Day. Lancet. 2005 Jun 11-17; 365(9476):1990-2. PMID: 15950704.
      View in: PubMed
    52. Mendelsohn J. Merging medicine with science: the birth of a targeted therapy in cancer. Ann Acad Med Singapore. 2004 Sep; 33(5 Suppl):S3. PMID: 15651180.
      View in: PubMed
    53. Mendelsohn J. EGF receptors as a target for cancer therapy. Trans Am Clin Climatol Assoc. 2004; 115:249-53; discussion 253-4. PMID: 17060971.
      View in: PubMed
    54. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003 Jul 15; 21(14):2787-99. PMID: 12860957.
      View in: PubMed
    55. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 2003 May 22; 22(21):3205-12. PMID: 12761490.
      View in: PubMed
    56. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: from the laboratory to the clinic. Cancer Immunol Immunother. 2003 May; 52(5):342-6. PMID: 12700950.
      View in: PubMed
    57. Herbst RS, Onn A, Mendelsohn J. The role of growth factor signaling in malignancy. Cancer Treat Res. 2003; 115:19-72. PMID: 12613192.
      View in: PubMed
    58. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):1S-13S. PMID: 12235219.
      View in: PubMed
    59. Albanell J, Codony-Servat J, Rojo F, Del Campo JM, Sauleda S, Anido J, Raspall G, Giralt J, Roselló J, Nicholson RI, Mendelsohn J, Baselga J. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 2001 Sep 01; 61(17):6500-10. PMID: 11522647.
      View in: PubMed
    60. Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla ER, Agrawal S, Mendelsohn J, Bianco AR, Tortora G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer. 2001 Jul 15; 93(2):172-8. PMID: 11410862.
      View in: PubMed
    61. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001 May; 7(5):1204-13. PMID: 11350885.
      View in: PubMed
    62. Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 2001 Apr 05; 20(15):1913-22. PMID: 11313939.
      View in: PubMed
    63. Mendelsohn J, Dinney CP. The Willet F. Whitmore, Jr., Lectureship: blockade of epidermal growth factor receptors as anticancer therapy. J Urol. 2001 Apr; 165(4):1152-7. PMID: 11257658.
      View in: PubMed
    64. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 2001 Mar; 8(1):3-9. PMID: 11350723.
      View in: PubMed
    65. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000 Dec 27; 19(56):6550-65. PMID: 11426640.
      View in: PubMed
    66. Mandal M, Vadlamudi R, Nguyen D, Wang RA, Costa L, Bagheri-Yarmand R, Mendelsohn J, Kumar R. Growth factors regulate heterogeneous nuclear ribonucleoprotein K expression and function. J Biol Chem. 2001 Mar 30; 276(13):9699-704. PMID: 11121407.
      View in: PubMed
    67. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis. J Biol Chem. 2000 Dec 15; 275(50):39451-7. PMID: 10967114.
      View in: PubMed
    68. Talukder AH, Jorgensen HF, Mandal M, Mishra SK, Vadlamudi RK, Clark BF, Mendelsohn J, Kumar R. Regulation of elongation factor-1alpha expression by growth factors and anti-receptor blocking antibodies. J Biol Chem. 2001 Feb 23; 276(8):5636-42. PMID: 11104760.
      View in: PubMed
    69. Bianco C, Bianco R, Tortora G, Damiano V, Guerrieri P, Montemaggi P, Mendelsohn J, De Placido S, Bianco AR, Ciardiello F. Antitumor activity of combined treatment of human cancer cells with ionizing radiation and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. Clin Cancer Res. 2000 Nov; 6(11):4343-50. PMID: 11106252.
      View in: PubMed
    70. Mendelsohn J. Use of an antibody to target geldanamycin. J Natl Cancer Inst. 2000 Oct 04; 92(19):1549-51. PMID: 11018081.
      View in: PubMed
    71. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J, Tortora G. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000 Sep; 6(9):3739-47. PMID: 10999768.
      View in: PubMed
    72. Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochim Biophys Acta. 2000 Jul 21; 1497(2):215-26. PMID: 10903426.
      View in: PubMed
    73. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer. 2000 Jun; 82(12):1991-9. PMID: 10864208.
      View in: PubMed
    74. Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1. Oncogene. 2000 May 11; 19(20):2423-9. PMID: 10828884.
      View in: PubMed
    75. Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy--the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res. 2000 Mar; 6(3):747-53. PMID: 10741693.
      View in: PubMed
    76. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000 Feb; 6(2):701-8. PMID: 10690556.
      View in: PubMed
    77. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D'Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000 Feb; 18(4):904-14. PMID: 10673534.
      View in: PubMed
    78. Fang M, Liu B, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Involvement of p21Waf1 in mediating inhibition of paclitaxel-induced apoptosis by epidermal growth factor in MDA-MB-468 human breast cancer cells. Anticancer Res. 2000 Jan-Feb; 20(1A):103-11. PMID: 10769641.
      View in: PubMed
    79. Mendelsohn J. Jeremiah Metzger Lecture. Targeted cancer therapy. Trans Am Clin Climatol Assoc. 2000; 111:95-110; discussion 110-1. PMID: 10881335.
      View in: PubMed
    80. Vadlamudi R, Adam L, Talukder A, Mendelsohn J, Kumar R. Serine phosphorylation of paxillin by heregulin-beta1: role of p38 mitogen activated protein kinase. Oncogene. 1999 Dec 02; 18(51):7253-64. PMID: 10602479.
      View in: PubMed
    81. Normanno N, Tortora G, De Luca A, Pomatico G, Casamassimi A, Agrawal S, Mendelsohn J, Bianco AR, Ciardiello F. Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonucleotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. Oncol Rep. 1999 Sep-Oct; 6(5):1105-9. PMID: 10425310.
      View in: PubMed
    82. Ye D, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res. 1999 Aug; 5(8):2171-7. PMID: 10473102.
      View in: PubMed
    83. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol. 1999 Aug; 26(4 Suppl 12):78-83. PMID: 10482197.
      View in: PubMed
    84. Chou JL, Fan Z, DeBlasio T, Koff A, Rosen N, Mendelsohn J. Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor. Breast Cancer Res Treat. 1999 Jun; 55(3):267-83. PMID: 10517171.
      View in: PubMed
    85. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res. 1999 Apr; 5(4):909-16. PMID: 10213228.
      View in: PubMed
    86. Tortora G, Caputo R, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Ciardiello F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin Cancer Res. 1999 Apr; 5(4):875-81. PMID: 10213224.
      View in: PubMed
    87. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene. 1999 Jan 21; 18(3):731-8. PMID: 9989823.
      View in: PubMed
    88. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999 Jan 14; 18(2):305-14. PMID: 9927187.
      View in: PubMed
    89. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem. 1998 Oct 23; 273(43):28238-46. PMID: 9774445.
      View in: PubMed
    90. Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res. 1998 Oct; 4(10):2545-50. PMID: 9796989.
      View in: PubMed
    91. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene. 1998 Aug 27; 17(8):999-1007. PMID: 9747879.
      View in: PubMed
    92. Bast RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma. 1998 Aug; 17(4):313-21. PMID: 9790065.
      View in: PubMed
    93. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, Bianco AR, Agrawal S, Mendelsohn J, Tortora G. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst. 1998 Jul 15; 90(14):1087-94. PMID: 9672257.
      View in: PubMed
    94. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998 Jul 01; 58(13):2825-31. PMID: 9661897.
      View in: PubMed
    95. Bromberg JF, Fan Z, Brown C, Mendelsohn J, Darnell JE. Epidermal growth factor-induced growth inhibition requires Stat1 activation. Cell Growth Differ. 1998 Jul; 9(7):505-12. PMID: 9690618.
      View in: PubMed
    96. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem. 1998 Jan 16; 273(3):1568-73. PMID: 9430697.
      View in: PubMed
    97. Fan Z, Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 1998 Jan; 10(1):67-73. PMID: 9466487.
      View in: PubMed
    98. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2703-7. PMID: 10068277.
      View in: PubMed
    99. Fan Z, Shang BY, Lu Y, Chou JL, Mendelsohn J. Reciprocal changes in p27(Kip1) and p21(Cip1) in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin Cancer Res. 1997 Nov; 3(11):1943-8. PMID: 9815583.
      View in: PubMed
    100. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW, Baselga J. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res. 1997 Nov; 3(11):2099-106. PMID: 9815602.
      View in: PubMed
    101. Hu G, Liu W, Mendelsohn J, Ellis LM, Radinsky R, Andreeff M, Deisseroth AB. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst. 1997 Sep 03; 89(17):1271-6. PMID: 9293917.
      View in: PubMed
    102. Wang H, Rubin M, Fenig E, DeBlasio A, Mendelsohn J, Yahalom J, Wieder R. Basic fibroblast growth factor causes growth arrest in MCF-7 human breast cancer cells while inducing both mitogenic and inhibitory G1 events. Cancer Res. 1997 May 01; 57(9):1750-7. PMID: 9135019.
      View in: PubMed
    103. Baselga J, Mendelsohn J. Type I receptor tyrosine kinases as targets for therapy in breast cancer. J Mammary Gland Biol Neoplasia. 1997 Apr; 2(2):165-74. PMID: 10882302.
      View in: PubMed
    104. Mendelsohn J, Fan Z. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst. 1997 Mar 05; 89(5):341-3. PMID: 9060954.
      View in: PubMed
    105. Ciardiello F, Damiano V, Bianco R, Bianco C, Fontanini G, De Laurentiis M, De Placido S, Mendelsohn J, Bianco AR, Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996 Dec 04; 88(23):1770-6. PMID: 8944008.
      View in: PubMed
    106. Slovin SF, Livingston PO, Rosen N, Sepp-Lorenzino L, Kelly WK, Mendelsohn J, Scher HI. Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach. Semin Oncol. 1996 Dec; 23(6 Suppl 14):41-8. PMID: 8996585.
      View in: PubMed
    107. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996 Nov; 19(6):419-27. PMID: 9041461.
      View in: PubMed
    108. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 1996 Aug 15; 56(16):3666-9. PMID: 8706005.
      View in: PubMed
    109. Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. Cytokine Growth Factor Rev. 1996 Aug; 7(2):133-41. PMID: 8899291.
      View in: PubMed
    110. Reisfeld RA, Gillies SD, Mendelsohn J, Varki NM, Becker JC. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res. 1996 Apr 15; 56(8):1707-12. PMID: 8620479.
      View in: PubMed
    111. Wu X, Rubin M, Fan Z, DeBlasio T, Soos T, Koff A, Mendelsohn J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 1996 Apr 04; 12(7):1397-403. PMID: 8622855.
      View in: PubMed
    112. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci U S A. 1996 Apr 02; 93(7):2702-7. PMID: 8610104.
      View in: PubMed
    113. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996 Mar; 14(3):737-44. PMID: 8622019.
      View in: PubMed
    114. Normanno N, Bianco C, Damiano V, de Angelis E, Selvam MP, Grassi M, Magliulo G, Tortora G, Bianco AR, Mendelsohn J, Salomon DS, Ciardiello F. Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res. 1996 Mar; 2(3):601-9. PMID: 9816209.
      View in: PubMed
    115. Baselga J, Mendelsohn J, Kim YM, Pandiella A. Autocrine regulation of membrane transforming growth factor-alpha cleavage. J Biol Chem. 1996 Feb 09; 271(6):3279-84. PMID: 8621731.
      View in: PubMed
    116. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov; 1(11):1311-8. PMID: 9815926.
      View in: PubMed
    117. Bentel JM, Lebwohl DE, Cullen KJ, Rubin MS, Rosen N, Mendelsohn J, Miller WH. Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells. J Cell Physiol. 1995 Oct; 165(1):212-21. PMID: 7559803.
      View in: PubMed
    118. Fan Z, Lu Y, Wu X, DeBlasio A, Koff A, Mendelsohn J. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. J Cell Biol. 1995 Oct; 131(1):235-42. PMID: 7559780.
      View in: PubMed
    119. Korutla L, Cheung JY, Mendelsohn J, Kumar R. Inhibition of ligand-induced activation of epidermal growth factor receptor tyrosine phosphorylation by curcumin. Carcinogenesis. 1995 Aug; 16(8):1741-5. PMID: 7634398.
      View in: PubMed
    120. Katzenellenbogen JA, Coleman RE, Hawkins RA, Krohn KA, Larson SM, Mendelsohn J, Osborne CK, Piwnica-Worms D, Reba RC, Siegel BA, et al. Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations. Clin Cancer Res. 1995 Aug; 1(8):921-32. PMID: 9816063.
      View in: PubMed
    121. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C. Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res. 1995 May; 1(5):545-50. PMID: 9816014.
      View in: PubMed
    122. Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest. 1995 Apr; 95(4):1897-905. PMID: 7706497.
      View in: PubMed
    123. Ciardiello F, Damiano V, Bianco C, di Isernia G, Ruggiero A, Caraglia M, Tagliaferri P, Baselga J, Mendelsohn J, Bianco AR, et al. Cooperative antiproliferative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells. Clin Cancer Res. 1995 Feb; 1(2):161-7. PMID: 9815969.
      View in: PubMed
    124. Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. Int J Cancer. 1995 Jan 03; 60(1):137-44. PMID: 7814146.
      View in: PubMed
    125. Rubin M, Fenig E, Rosenauer A, Menendez-Botet C, Achkar C, Bentel JM, Yahalom J, Mendelsohn J, Miller WH. 9-Cis retinoic acid inhibits growth of breast cancer cells and down-regulates estrogen receptor RNA and protein. Cancer Res. 1994 Dec 15; 54(24):6549-56. PMID: 7987855.
      View in: PubMed
    126. Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem. 1994 Nov 04; 269(44):27595-602. PMID: 7961676.
      View in: PubMed
    127. Sturgis EM, Sacks PG, Masui H, Mendelsohn J, Schantz SP. Effects of antiepidermal growth factor receptor antibody 528 on the proliferation and differentiation of head and neck cancer. Otolaryngol Head Neck Surg. 1994 Nov; 111(5):633-43. PMID: 7970803.
      View in: PubMed
    128. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther. 1994 Oct; 64(1):127-54. PMID: 7846112.
      View in: PubMed
    129. Kumar R, Mendelsohn J. Reduced expression of c-erbB2 gene product in human mammary carcinoma SK-BR-3 cells treated with interferon-gamma and tumor necrosis factor-alpha. Anticancer Res. 1994 May-Jun; 14(3A):1001-8. PMID: 7915505.
      View in: PubMed
    130. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat. 1994 Jan; 29(1):127-38. PMID: 8018961.
      View in: PubMed
    131. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells. Immunol Lett. 1993 Dec; 39(1):91-9. PMID: 8144194.
      View in: PubMed
    132. Meyers MB, Yu P, Mendelsohn J. Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. Biochem Pharmacol. 1993 Nov 17; 46(10):1841-8. PMID: 7902716.
      View in: PubMed
    133. Fan Z, Mendelsohn J, Masui H, Kumar R. Regulation of epidermal growth factor receptor in NIH3T3/HER14 cells by antireceptor monoclonal antibodies. J Biol Chem. 1993 Oct 05; 268(28):21073-9. PMID: 8407944.
      View in: PubMed
    134. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993 Oct 01; 53(19):4637-42. PMID: 8402640.
      View in: PubMed
    135. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother. 1993 Oct; 37(5):343-9. PMID: 8402738.
      View in: PubMed
    136. Fan Z, Masui H, Altas I, Mendelsohn J. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1993 Sep 15; 53(18):4322-8. PMID: 8364927.
      View in: PubMed
    137. Stampfer MR, Pan CH, Hosoda J, Bartholomew J, Mendelsohn J, Yaswen P. Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. Exp Cell Res. 1993 Sep; 208(1):175-88. PMID: 7689475.
      View in: PubMed
    138. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst. 1993 Aug 18; 85(16):1327-33. PMID: 8340945.
      View in: PubMed
    139. Chen LL, Narayanan R, Hibbs MS, Benn PA, Clawson ML, Lu G, Rhim JS, Greenberg B, Mendelsohn J. Altered epidermal growth factor signal transduction in activated Ha-ras-transformed human keratinocytes. Biochem Biophys Res Commun. 1993 May 28; 193(1):167-74. PMID: 8503904.
      View in: PubMed
    140. Masui H, Castro L, Mendelsohn J. Consumption of EGF by A431 cells: evidence for receptor recycling. J Cell Biol. 1993 Jan; 120(1):85-93. PMID: 8416997.
      View in: PubMed
    141. Fong CJ, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM. Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res. 1992 Nov 01; 52(21):5887-92. PMID: 1394216.
      View in: PubMed
    142. Atlas I, Mendelsohn J, Baselga J, Fair WR, Masui H, Kumar R. Growth regulation of human renal carcinoma cells: role of transforming growth factor alpha. Cancer Res. 1992 Jun 15; 52(12):3335-9. PMID: 1596891.
      View in: PubMed
    143. Klein SB, Fisher GJ, Jensen TC, Mendelsohn J, Voorhees JJ, Elder JT. Regulation of TGF-alpha expression in human keratinocytes: PKC-dependent and -independent pathways. J Cell Physiol. 1992 May; 151(2):326-36. PMID: 1572907.
      View in: PubMed
    144. Karnes WE, Walsh JH, Wu SV, Kim RS, Martin MG, Wong HC, Mendelsohn J, Park JG, Cuttitta F. Autonomous proliferation of colon cancer cells that coexpress transforming growth factor alpha and its receptor. Variable effects of receptor-blocking antibody. Gastroenterology. 1992 Feb; 102(2):474-85. PMID: 1732118.
      View in: PubMed
    145. Goldkorn T, Mendelsohn J. Transforming growth factor beta modulates phosphorylation of the epidermal growth factor receptor and proliferation of A431 cells. Cell Growth Differ. 1992 Feb; 3(2):101-9. PMID: 1504015.
      View in: PubMed
    146. Mendelsohn J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J Natl Cancer Inst Monogr. 1992; (13):125-31. PMID: 1389685.
      View in: PubMed
    147. Mendelsohn J. Immunotoxins: prospects and problems. J Clin Oncol. 1991 Dec; 9(12):2088-90. PMID: 1960548.
      View in: PubMed
    148. Goldkorn T, Dressler KA, Muindi J, Radin NS, Mendelsohn J, Menaldino D, Liotta D, Kolesnick RN. Ceramide stimulates epidermal growth factor receptor phosphorylation in A431 human epidermoid carcinoma cells. Evidence that ceramide may mediate sphingosine action. J Biol Chem. 1991 Aug 25; 266(24):16092-7. PMID: 1874747.
      View in: PubMed
    149. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM. Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res. 1991 Jun 01; 51(11):2780-5. PMID: 2032218.
      View in: PubMed
    150. Van de Vijver MJ, Kumar R, Mendelsohn J. Ligand-induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J Biol Chem. 1991 Apr 25; 266(12):7503-8. PMID: 2019581.
      View in: PubMed
    151. Kumar R, Mendelsohn J. Polypeptide growth factors in the regulation of human tumor cell proliferation. Curr Opin Oncol. 1991 Feb; 3(1):70-4. PMID: 1675128.
      View in: PubMed
    152. Kumar R, Shepard HM, Mendelsohn J. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Mol Cell Biol. 1991 Feb; 11(2):979-86. PMID: 1671297.
      View in: PubMed
    153. Divgi CR, Welt S, Kris M, Real FX, Yeh SD, Gralla R, Merchant B, Schweighart S, Unger M, Larson SM, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991 Jan 16; 83(2):97-104. PMID: 1988695.
      View in: PubMed
    154. Sunada H, Peacock J, Mendelsohn J. Ligand induced internalization of epidermal growth factor receptors by A431 cells decreases at high cell densities in culture. Growth Factors. 1991; 5(1):45-55. PMID: 1772661.
      View in: PubMed
    155. Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents. J Steroid Biochem Mol Biol. 1990 Dec 20; 37(6):889-92. PMID: 2285602.
      View in: PubMed
    156. Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol. 1990 Oct; 1(5):339-44. PMID: 2103507.
      View in: PubMed
    157. Kumar R, Mendelsohn J. Growth regulation of A431 cells. Modulation of expression of transforming growth factor-alpha mRNA and 2',5'-oligoadenylate synthetase activity. J Biol Chem. 1990 Mar 15; 265(8):4578-82. PMID: 2106521.
      View in: PubMed
    158. Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H, Demers L. Role of transforming growth factor-alpha-related peptides in the autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol, prolactin, and progesterone. Breast Cancer Res Treat. 1990 Feb; 15(2):73-83. PMID: 2322651.
      View in: PubMed
    159. Gabrilove J, Mendelsohn J. Growth factors in human cancer. Curr Opin Oncol. 1990 Feb; 2(1):163-70. PMID: 1710146.
      View in: PubMed
    160. Sunada H, Yu P, Peacock JS, Mendelsohn J. Modulation of tyrosine, serine, and threonine phosphorylation and intracellular processing of the epidermal growth factor receptor by antireceptor monoclonal antibody. J Cell Physiol. 1990 Feb; 142(2):284-92. PMID: 1689318.
      View in: PubMed
    161. Bates SE, Valverius EM, Ennis BW, Bronzert DA, Sheridan JP, Stampfer MR, Mendelsohn J, Lippman ME, Dickson RB. Expression of the transforming growth factor-alpha/epidermal growth factor receptor pathway in normal human breast epithelial cells. Endocrinology. 1990 Jan; 126(1):596-607. PMID: 2294006.
      View in: PubMed
    162. Chen LL, Dean A, Jenkinson T, Mendelsohn J. Effect of transforming growth factor-beta 1 on proliferation and induction of hemoglobin accumulation in K-562 cells. Blood. 1989 Nov 15; 74(7):2368-75. PMID: 2804370.
      View in: PubMed
    163. Goldenberg A, Masui H, Divgi C, Kamrath H, Pentlow K, Mendelsohn J. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody. J Natl Cancer Inst. 1989 Nov 01; 81(21):1616-25. PMID: 2795690.
      View in: PubMed
    164. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J, et al. Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol. 1989 Nov; 3(11):1830-8. PMID: 2608059.
      View in: PubMed
    165. Kumar R, Mendelsohn J. Role of 2'-5'-oligoadenylate synthetase in gamma-interferon-mediated growth inhibition of A431 cells. Cancer Res. 1989 Sep 15; 49(18):5180-4. PMID: 2504485.
      View in: PubMed
    166. Masui H, Kamrath H, Apell G, Houston LL, Mendelsohn J. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain. Cancer Res. 1989 Jul 01; 49(13):3482-8. PMID: 2786451.
      View in: PubMed
    167. Mendelsohn J. Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications. Trans Am Clin Climatol Assoc. 1989; 100:31-8. PMID: 3077575.
      View in: PubMed
    168. Palombella VJ, Mendelsohn J, Vilcek J. Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor. J Cell Physiol. 1988 Apr; 135(1):23-31. PMID: 3259236.
      View in: PubMed
    169. Mendelsohn J. Growth factor receptors as targets for antitumor therapy with monoclonal antibodies. Prog Allergy. 1988; 45:147-60. PMID: 3064094.
      View in: PubMed
    170. Sobol RE, Astarita RW, Hofeditz C, Masui H, Fairshter R, Royston I, Mendelsohn J. Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. J Natl Cancer Inst. 1987 Sep; 79(3):403-7. PMID: 3476783.
      View in: PubMed
    171. Castagnola J, MacLeod C, Sunada H, Mendelsohn J, Taetle R. Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells. J Cell Physiol. 1987 Sep; 132(3):492-500. PMID: 3498729.
      View in: PubMed
    172. Vollmar AM, Banker DE, Mendelsohn J, Herschman HR. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor. J Cell Physiol. 1987 Jun; 131(3):418-25. PMID: 3496342.
      View in: PubMed
    173. Sauvage CA, Mendelsohn JC, Lesley JF, Trowbridge IS. Effects of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res. 1987 Feb 01; 47(3):747-53. PMID: 3802079.
      View in: PubMed
    174. Mendelsohn J, Masui H, Goldenberg A. Anti-epidermal growth factor receptor monoclonal antibodies may inhibit A431 tumor cell proliferation by blocking an autocrine pathway. Trans Assoc Am Physicians. 1987; 100:173-8. PMID: 3502661.
      View in: PubMed
    175. Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 1986 Nov; 46(11):5592-8. PMID: 3756906.
      View in: PubMed
    176. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J. Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res. 1986 Sep; 46(9):4726-31. PMID: 3015394.
      View in: PubMed
    177. Santon JB, Cronin MT, MacLeod CL, Mendelsohn J, Masui H, Gill GN. Effects of epidermal growth factor receptor concentration on tumorigenicity of A431 cells in nude mice. Cancer Res. 1986 Sep; 46(9):4701-5. PMID: 3015393.
      View in: PubMed
    178. Sunada H, Magun BE, Mendelsohn J, MacLeod CL. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A. 1986 Jun; 83(11):3825-9. PMID: 2424012.
      View in: PubMed
    179. MacLeod CL, Luk A, Castagnola J, Cronin M, Mendelsohn J. EGF induces cell cycle arrest of A431 human epidermoid carcinoma cells. J Cell Physiol. 1986 Apr; 127(1):175-82. PMID: 3007537.
      View in: PubMed
    180. Taetle R, Castagnola J, Mendelsohn J. Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res. 1986 Apr; 46(4 Pt 1):1759-63. PMID: 3004704.
      View in: PubMed
    181. Yu AL, Mendelsohn J, Matsumoto SS. Induction of complete remission in T-cell acute lymphoblastic leukemia with deoxycoformycin (dcf) and 9-beta-D-arabinofuranosyladenine (ara-A). Adv Exp Med Biol. 1986; 195 Pt A:491-6. PMID: 3487920.
      View in: PubMed
    182. Sunada H, MacLeod C, Mendelsohn J. A direct radioimmunoassay for human epidermal growth factor receptor using 32P-autophosphorylated receptor. Anal Biochem. 1985 Sep; 149(2):438-47. PMID: 3000217.
      View in: PubMed
    183. Taetle R, Rhyner K, Castagnola J, To D, Mendelsohn J. Role of transferrin, Fe, and transferrin receptors in myeloid leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody. J Clin Invest. 1985 Mar; 75(3):1061-7. PMID: 2984253.
      View in: PubMed
    184. Gooi HC, Hounsell EF, Lax I, Kris RM, Libermann TA, Schlessinger J, Sato JD, Kawamoto T, Mendelsohn J, Feizi T. The carbohydrate specificities of the monoclonal antibodies 29.1, 455 and 3C1B12 to the epidermal growth factor receptor of A431 cells. Biosci Rep. 1985 Jan; 5(1):83-94. PMID: 2580573.
      View in: PubMed
    185. Fagnani R, Cooper HL, Mendelsohn J. Purification of human interleukin 2 to apparent homogeneity and partial characterization of its receptor. Anal Biochem. 1984 Nov 01; 142(2):487-96. PMID: 6442106.
      View in: PubMed
    186. Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS, Gill GN. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A431 cells. J Biol Chem. 1984 Jun 25; 259(12):7761-6. PMID: 6330080.
      View in: PubMed
    187. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem. 1984 Jun 25; 259(12):7755-60. PMID: 6330079.
      View in: PubMed
    188. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 1984 Mar; 44(3):1002-7. PMID: 6318979.
      View in: PubMed
    189. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983 Dec; 1(5):511-29. PMID: 6094961.
      View in: PubMed
    190. Rice C, Hudig D, Lad P, Mendelsohn J. Ethanol activation of human natural cytotoxicity. Immunopharmacology. 1983 Dec; 6(4):303-16. PMID: 6360950.
      View in: PubMed
    191. Mendelsohn J, Trowbridge I, Castagnola J. Inhibition of human lymphocyte proliferation by monoclonal antibody to transferrin receptor. Blood. 1983 Oct; 62(4):821-6. PMID: 6309286.
      View in: PubMed
    192. Taetle R, To D, Mendelsohn J. In vitro sensitivity to steroid hormones and cytotoxic agents of normal and malignant lymphocyte colony-forming cells. Cancer Res. 1983 Aug; 43(8):3553-8. PMID: 6602652.
      View in: PubMed
    193. Taetle R, To D, Caviles A, Norby SW, Mendelsohn J. Characterization of normal peripheral blood lymphocyte colony-forming cells: cell cycle status, surface markers, and cellular growth requirements. Blood. 1983 Mar; 61(3):548-55. PMID: 6824787.
      View in: PubMed
    194. Kawamoto T, Sato JD, Le A, Polikoff J, Sato GH, Mendelsohn J. Growth stimulation of A431 cells by epidermal growth factor: identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci U S A. 1983 Mar; 80(5):1337-41. PMID: 6298788.
      View in: PubMed
    195. Young JA, Dillman RO, Seagren SL, Taetle R, Rentschler RE, Lea JW, Lehar TJ, Green MR, Stanton W, Mendelsohn J, Royston I. Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell carcinoma of the lung. Cancer Treat Rep. 1982 Jun; 66(6):1399-401. PMID: 6282459.
      View in: PubMed
    196. Dillman RO, Taetle R, Seagren S, Royston I, Koziol J, Mendelsohn J. Extensive disease small cell carcinoma of the lung: trial of non-cross resistant chemotherapy and consolidation radiotherapy. Cancer. 1982 May 15; 49(10):2003-8. PMID: 6280831.
      View in: PubMed
    197. Taetle R, Richardson D, To D, Royston I, Mendelsohn J. Colony-forming assay for circulating chronic lymphocytic leukemia cells. Leuk Res. 1982; 6(3):335-44. PMID: 7121052.
      View in: PubMed
    198. Rice C, Hudig D, Newton RS, Mendelsohn J. Effect of unsaturated fatty acids on human lymphocytes: disparate influences of oleic and linolenic acids on natural cytotoxicity. Clin Immunol Immunopathol. 1981 Sep; 20(3):389-401. PMID: 6978787.
      View in: PubMed
    199. Hudig D, Djobadze M, Redelman D, Mendelsohn J. Active tumor cell resistance to human natural killer lymphocyte attack. Cancer Res. 1981 Jul; 41(7):2803-8. PMID: 7248944.
      View in: PubMed
    200. Hudig D, Haverty T, Fulcher C, Redelman D, Mendelsohn J. Inhibition of human natural cytotoxicity by macromolecular antiproteases. J Immunol. 1981 Apr; 126(4):1569-74. PMID: 6970780.
      View in: PubMed
    201. Howell SB, Chu BB, Wung WE, Metha BM, Mendelsohn J. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest. 1981 Apr; 67(4):1161-70. PMID: 6970753.
      View in: PubMed
    202. De Vries JE, Vyth FA, Mendelsohn J. T-cell growth factor-mediated proliferation of lymphocytes from a T-chronic lymphocytic leukaemia patient lacking mitogen and alloantigen responsiveness. Clin Exp Immunol. 1981 Feb; 43(2):302-10. PMID: 6456094.
      View in: PubMed
    203. Taetle R, Mendelsohn J. An emerging role for prostaglandin E1 in regulation of granulopoiesis. Leuk Res. 1981; 5(6):511-2. PMID: 7199102.
      View in: PubMed
    204. Mendelsohn J, Hudig D, Castagnola J. DNA synthesis and proliferation of human lymphocytes in vitro: III. Fate of cycling cells in aging cultures of phytohemagglutinin stimulated human lymphocytes. J Cell Physiol. 1981 Jan; 106(1):13-22. PMID: 7204506.
      View in: PubMed
    205. Taetle R, Guittard JP, Mendelsohn JM. Abnormal modulation of granulocyte/macrophage progenitor proliferation by prostaglandin E in chronic myeloproliferative disorders. Exp Hematol. 1980 Nov; 8(10):1190-1201. PMID: 6971757.
      View in: PubMed
    206. Howell SB, Chu B, Mendelsohn J, Carson DA, Kung FH, Seegmiller JE. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. J Natl Cancer Inst. 1980 Aug; 65(2):277-84. PMID: 6967527.
      View in: PubMed
    207. de Vries JE, Mendelsohn J, Bont WS. The role of target cells, monocytes, and Fc receptor-bearing lymphocytes in human spontaneous cell-mediated cytotoxicity and antibody-dependent cellular cytotoxicity. J Immunol. 1980 Jul; 125(1):396-405. PMID: 7381206.
      View in: PubMed
    208. Howell SB, Taetle R, Mendelsohn J. Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and acute nonlymphocytic leukemia. Blood. 1980 Mar; 55(3):505-10. PMID: 6965593.
      View in: PubMed
    209. Green MH, Brooks TL, Mendelsohn J, Howell SB. Antitumor activity of L-canavanine against L1210 murine leukemia. Cancer Res. 1980 Mar; 40(3):535-7. PMID: 7471074.
      View in: PubMed
    210. Byfield JE, Barone R, Mendelsohn J, Frankel S, Quinol L, Sharp T, Seagren S. Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer. Cancer. 1980 Feb 15; 45(4):703-8. PMID: 6153563.
      View in: PubMed
    211. de Vries JE, Mendelsohn J, Bont WS. Requirement for monocytes in the spontaneous cytotoxic effects of human lymphocytes against non-lymphoid target cells. Nature. 1980 Feb 07; 283(5747):574-6. PMID: 7354840.
      View in: PubMed
    212. de Vries JE, Mendelsohn J, Bont WS. The requirement for monocytes in spontaneous cytotoxicity by lymphocytes from healthy donors and melanoma patients. Int J Cancer. 1980 Jan 15; 25(1):73-84. PMID: 7399746.
      View in: PubMed
    213. Taetle R, Mendelsohn J. Modulation of normal and abnormal myeloid progenitor proliferation by cyclic nucleotides and PGE1. Blood Cells. 1980; 6(4):701-18. PMID: 6258672.
      View in: PubMed
    214. Newman JG, Newman TB, Bowie LJ, Mendelsohn J. An examination of the role of vitamin E in glucose-6-phosphate dehydrogenase deficiency. Clin Biochem. 1979 Oct; 12(5):149-51. PMID: 519843.
      View in: PubMed
    215. Taetle R, Lane TA, Mendelsohn J. Drug-induced agranulocytosis: in vitro evidence for immune suppression of granulopoiesis and a cross-reacting lymphocyte antibody. Blood. 1979 Aug; 54(2):501-12. PMID: 454851.
      View in: PubMed
    216. Mendelsohn J, Nordberg J. Adenylate cyclase in thymus-derived and bone marrow-derived lymphocytes from normal donors and patients with chronic lymphocytic leukemia. J Clin Invest. 1979 Jun; 63(6):1124-32. PMID: 221534.
      View in: PubMed
    217. de Vries JE, Caviles AP, Bont WS, Mendelsohn J. The role of monocytes in human lymphocyte activation by mitogens. J Immunol. 1979 Mar; 122(3):1099-107. PMID: 448072.
      View in: PubMed
    218. Shiftan TA, Mendelsohn J. Hodgkin's disease and anergy. Blut. 1979 Jan 22; 38(1):1-7. PMID: 365274.
      View in: PubMed
    219. Taetle R, Mendelsohn J, Green MR. Hypercalcemia and tamoxifen readministered. Ann Intern Med. 1978 Aug; 89(2):287. PMID: 677600.
      View in: PubMed
    220. Sell S, Mendelsohn J. Transfer of specific immunity with RNA. Arch Pathol Lab Med. 1978 May; 102(5):217-22. PMID: 306237.
      View in: PubMed
    221. Shiftan TA, Caviles AP, Mendelsohn J. Spontaneous lymphocyte proliferation and depressed cellular immunity in Hodgkin's disease. Clin Exp Immunol. 1978 Apr; 32(1):144-52. PMID: 668190.
      View in: PubMed
    222. Bernheim JL, Mendelsohn J. DNA synthesis and proliferation of human lymphocytes in vitro. II. Characterization of the DNA newly synthesized after phytohemagglutinin stimulation. J Immunol. 1978 Mar; 120(3):963-70. PMID: 632596.
      View in: PubMed
    223. Bernheim JL, Dorian RE, Mendelsohn J. DNA synthesis and proliferation of human lymphocytes in vitro. I. Cell kinetics of response to phytohemagglutinin. J Immunol. 1978 Mar; 120(3):955-62. PMID: 632595.
      View in: PubMed
    224. Dorian R, Bernheim JL, Mendelsohn J. Quantification of entry into and exit from the cell cycle in human lymphocyte cultures. Cell Tissue Kinet. 1978 Jan; 11(1):33-44. PMID: 624116.
      View in: PubMed
    225. Shiftan TA, Mendelsohn J. The circulating "atypical" lymphocyte. Hum Pathol. 1978 Jan; 9(1):51-61. PMID: 631844.
      View in: PubMed
    226. Linthicum DS, Elson E, Mendelsohn J, Sell S. Endocytosis and exocytosis of phytohemagglutinin (PHA) cell surface receptors of human lymphocytes during blast transformation. Exp Cell Res. 1977 Dec; 110(2):237-50. PMID: 304009.
      View in: PubMed
    227. Bernheim JL, Mendelsohn J, Kelley MF, Dorian R. Kinetics of cell death and disintegration in human lymphocyte cultures. Proc Natl Acad Sci U S A. 1977 Jun; 74(6):2536-40. PMID: 267948.
      View in: PubMed
    228. Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine and guanosine metabolism during phytohemagglutinin induced transformation of human lymphocytes. Adv Exp Med Biol. 1977; 76A:441-7. PMID: 404852.
      View in: PubMed
    229. Mendelsohn J, Multer MM, Bernheim JL. Inhibition of human lymphocyte stimulation by steroid hormones: cytokinetic mechanisms. Clin Exp Immunol. 1977 Jan; 27(1):127-34. PMID: 849646.
      View in: PubMed
    230. Snyder FF, Mendelsohn J, Seegmiller JE. Adenosine metabolism in phytohemagglutinin-stimulated human lymphocytes. J Clin Invest. 1976 Sep; 58(3):654-66. PMID: 956393.
      View in: PubMed
    231. Mendelsohn J, Castagnola JM, Goulian M. On the mechanism for formation of RNA . DNA complexes from lymphocytes. Biochim Biophys Acta. 1975 Oct 15; 407(3):283-91. PMID: 1186171.
      View in: PubMed
    232. Mendelsohn J, Fox RM, Goulian M, Barbosa E. Nascent DNA from phytohemagglutinin-stimulated human lymphocytes. Immunol Commun. 1975; 4(4):373-85. PMID: 1184115.
      View in: PubMed
    233. Fox RM, Mendelsohn J, Barbosa E, Goulian M. RNA in nascent DNA from cultured human lymphocytes. Nat New Biol. 1973 Oct 24; 245(147):234-7. PMID: 4518365.
      View in: PubMed
    234. Rosenfeld MG, Abrass IB, Mendelsohn J, Miller HI, Holland J. Poly(A): possible role in translation of poly(A)-rich RNA. Proc Soc Exp Biol Med. 1973 Oct 01; 144(1):215-9. PMID: 4771562.
      View in: PubMed
    235. Mendelsohn J, Multer MM, Boone RF. Enhanced effects of prostaglandin E1 and dibutyryl cyclic AMP upon human lymphocytes in the presence of cortisol. J Clin Invest. 1973 Sep; 52(9):2129-37. PMID: 4353772.
      View in: PubMed
    236. Wong-Staal F, Mendelsohn J, Goulian M. Ribonucleotides in closed circular mitochondrial DNA from HeLa cells. Biochem Biophys Res Commun. 1973 Jul 02; 53(1):140-8. PMID: 4582369.
      View in: PubMed
    237. Rosenfeld MG, Abrass JB, Mendelsohn J, Ross BA, Boone RF, Garren LD. Control of transcription of RNA rich in polyadenylic acid in human lymphocytes. Proc Natl Acad Sci U S A. 1972 Aug; 69(8):2306-11. PMID: 4340753.
      View in: PubMed
    238. Mendelsohn J, Skinner A, Kornfeld S. The rapid induction by phytohemagglutinin of increased alpha-aminoisobutyric acid uptake by lymphocytes. J Clin Invest. 1971 Apr; 50(4):818-26. PMID: 4100684.
      View in: PubMed
    239. Dawson DM, Alper CA, Seidman J, Mendelsohn J. Measurement of serum enzyme turnover rates. Ann Intern Med. 1969 Apr; 70(4):799-805. PMID: 5771537.
      View in: PubMed
    240. Mendelsohn J, Moore DE, Salzman NP. Separation of isolated Chinese hamster metaphase chromosomes into three size-groups. J Mol Biol. 1968 Feb 28; 32(1):101-12. PMID: 4230571.
      View in: PubMed
    241. Salzman NP, Moore DE, Mendelsohn J. Isolation and characterization of human metaphase chromosomes. Proc Natl Acad Sci U S A. 1966 Nov; 56(5):1449-56. PMID: 5230305.
      View in: PubMed
    242. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.
    243. From Bench to Bedside with Targeted Therapies.
    244. Phase I trials of thymosin fraction 5 and thymosin α1. Journal of Biological Response Modifiers. 1:35-41.
    245. Lymphocyte PHA and PPD stimulation as an in vitro model for recruitment. Cancer Treatment Reports. 60:1986-1987.
    246. Clinical cancer research. Clinical Cancer Research. 5:1.
    247. Preface. Unknown Journal.
    248. Kinetics of DNA synthesis, cell proliferation and cell death in human lymphocyte stimulation by phytohemagglutinin (PHA). Federation Proceedings. 35.
    249. Chapter 12 Isolation and Fractionation of Metaphase Chromosomes. Methods in Cell Biology. 3:277-292.
    250. The right drugs at the right time for the right patient. Drug Discovery Today.
    251. Introduction to stem cells and cancer. Unknown Journal.
    252. Modulation of cytosine arabinoside triphosphate (ara-CTP) and trinucleotide pools in a human acute leukemia cell line (HL-60) by thymidine (dThd) and hydroxyurea (HU). 844.
    253. Anti-EGF receptor monoclonal antibody 528 inhibits proliferation of a subset of human tumor cells in culture and in xenografts.
    254. Editorial. Clinical Cancer Research. 1995:7-675.
    255. Detection of epidermal growth factor receptor (EGFr) on cultured human cell using monoclonal antibodies (mAbs). Federation Proceedings. 44.
    256. Deconvolution of microfluorometric histograms with B splines. Journal of the American Statistical Association. 77:748-753.
    257. The Molecular Basis of Cancer.
    258. A direct radioimmune assay for human EGF receptor. Federation Proceedings. 44.
    259. Foreword. xv-xv.
    260. Commentary on "Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts" (a follow up). Cancer Research. 76:5192-5194.
    261. Effects of unsaturated fatty acids and ethanol on human lymphocyte natural cytotoxicity (NK). Federation Proceedings. 40.
    262. Challenges in initiating and conducting personalized cancer therapy trials. Annals of Oncology. 26:1791-1798.
    263. EGF receptor blockade as anticancer therapy. Cancer Research Therapy and Control. 7:195-197.
    264. Thymidine (TdR) as a potential chemotherapeutic agent. 509-510.
    265. The Molecular basis of cancer.
    266. A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. Oncotarget. 6:14139-14152.
    267. Nucleoside requirements for the protection of human marrow from methotrexate (MTX).
    268. Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel. Oncotarget. 7:71686-71695.
    269. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.
    270. Growth factors in lung cancer. Current status and implications for therapy. Growth Factors and Cytokines in Health and Disease. 3:355-380.
    271. Preface. Unknown Journal.
    272. Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas. Journal of Experimental and Clinical Cancer Research. 11:83-91.
    273. Shared genomic data sets. Oncology Report. 10.
    274. Erratum. Journal of the National Cancer Institute. 108.
    275. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology. 27:795-800.
    276. QUANTIFICATION OF ENTRY INTO AND EXIT FROM THE CELL CYCLE IN HUMAN LYMPHOCYTE CULTURES. Cell Proliferation. 11:33-44.
    277. Role of AKT in chemotherapy-mediated cytotoxicity in MCF-7 breast cancer cells. Breast Cancer Research and Treatment. 69:275.
    278. The Molecular Basis of Cancer.
    279. Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 7:76362-76373.
    280. New feature. Clinical Cancer Research. 7:1107.
    281. Moving discovery into clinical practice. Clinical Cancer Research. 10:8129.
    282. Monoclonal antibodies to the EGF receptor selectively inhibit the growth of human tumor cells. Federation Proceedings. 44.
    283. Growth factors, hormones, cell growth, surgery, subspecialty investigation. Clinical Cancer Research. 9:3517.
    284. The roles of transferrin(TF), transferrin receptors (TFR) and FE in hemopoietic cell growth.
    285. Nascent DNA from phytohemagglutinin-stimulated human lymphocytes. Immunological Investigations. 4:373-385.
    286. Clinical Cancer Research. Clinical Cancer Research. 7:1.
    287. Cytotoxic and antitumor activity of canavanine (CANA).
    288. From Bench to Bedside with Targeted Therapies. 521-530.
    289. Characterization and drug treatment of human lymphocytes in a colony assay.
    290. Cancer biology. Current Opinion in Oncology. 3:63-64.
    291. Culture of normal and leukemic human lymphocyte colonies.
    MENDELSOHN's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description